Astellas Pharma vs Zhejiang Huahai Pharmaceutical: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Astellas Pharma Inc. (4503.JP)

Q3 202615 Jul – 2 Sep 2026

▲3▼1

Astellas: strong Q1 and new bladder-cancer approval, but Trump pricing deal adds pressure

FDA approves PADCEV plus Keytruda for muscle-invasive bladder cancer The FDA approved Astellas and Pfizer's PADCEV combined with Keytruda for muscle-invasive bladder cancer, the first platinum-free regimen for this disease. This widens the patient group that can use the treatment, which should lift future sales of this key Astellas drug.
A new US approval directly expands the market for an Astellas product, a core driver of future revenue.
Q1 profit surges and full-year guidance raised Astellas reported first-quarter profit of 141.81 billion yen, more than double last year, with revenue up sharply. It guided fiscal 2027 revenue to grow 3.8% to 2.22 trillion yen and profit to rise 2.9%. Strong results and upbeat guidance support the stock.
Earnings and guidance are the most direct fundamental driver of the share price.
Health Canada approves Keytruda plus enfortumab vedotin for bladder cancer Health Canada approved Merck's Keytruda with enfortumab vedotin, which Astellas co-developed, for muscle-invasive bladder cancer. This adds another country where the combination can be sold, supporting Astellas's share of revenue from the drug.
A new geographic approval broadens the commercial reach of an Astellas-partnered therapy.
Astellas joins Trump's Medicaid most-favored-nation pricing deals Astellas agreed to give Medicaid the lowest prices it charges anywhere and to help build US manufacturing in exchange for tariff relief. This limits future US pricing power and could pressure revenue, though tariff relief and goodwill are partial offsets.
The pricing agreement is a direct regulatory hit to Astellas's US drug pricing and a key new overhang.

August 202615 Jul – 2 Sep 2026

▲3▼1

Astellas: strong Q1 and new bladder-cancer approval, but Trump pricing deal adds pressure

FDA approves PADCEV plus Keytruda for muscle-invasive bladder cancer The FDA approved Astellas and Pfizer's PADCEV combined with Keytruda for muscle-invasive bladder cancer, the first platinum-free regimen for this disease. This widens the patient group that can use the treatment, which should lift future sales of this key Astellas drug.
A new US approval directly expands the market for an Astellas product, a core driver of future revenue.
Q1 profit surges and full-year guidance raised Astellas reported first-quarter profit of 141.81 billion yen, more than double last year, with revenue up sharply. It guided fiscal 2027 revenue to grow 3.8% to 2.22 trillion yen and profit to rise 2.9%. Strong results and upbeat guidance support the stock.
Earnings and guidance are the most direct fundamental driver of the share price.
Health Canada approves Keytruda plus enfortumab vedotin for bladder cancer Health Canada approved Merck's Keytruda with enfortumab vedotin, which Astellas co-developed, for muscle-invasive bladder cancer. This adds another country where the combination can be sold, supporting Astellas's share of revenue from the drug.
A new geographic approval broadens the commercial reach of an Astellas-partnered therapy.
Astellas joins Trump's Medicaid most-favored-nation pricing deals Astellas agreed to give Medicaid the lowest prices it charges anywhere and to help build US manufacturing in exchange for tariff relief. This limits future US pricing power and could pressure revenue, though tariff relief and goodwill are partial offsets.
The pricing agreement is a direct regulatory hit to Astellas's US drug pricing and a key new overhang.

Latest15 Jul – 2 Sep 2026

▲3▼1

Astellas: strong Q1 and new bladder-cancer approval, but Trump pricing deal adds pressure

FDA approves PADCEV plus Keytruda for muscle-invasive bladder cancer The FDA approved Astellas and Pfizer's PADCEV combined with Keytruda for muscle-invasive bladder cancer, the first platinum-free regimen for this disease. This widens the patient group that can use the treatment, which should lift future sales of this key Astellas drug.
A new US approval directly expands the market for an Astellas product, a core driver of future revenue.
Q1 profit surges and full-year guidance raised Astellas reported first-quarter profit of 141.81 billion yen, more than double last year, with revenue up sharply. It guided fiscal 2027 revenue to grow 3.8% to 2.22 trillion yen and profit to rise 2.9%. Strong results and upbeat guidance support the stock.
Earnings and guidance are the most direct fundamental driver of the share price.
Health Canada approves Keytruda plus enfortumab vedotin for bladder cancer Health Canada approved Merck's Keytruda with enfortumab vedotin, which Astellas co-developed, for muscle-invasive bladder cancer. This adds another country where the combination can be sold, supporting Astellas's share of revenue from the drug.
A new geographic approval broadens the commercial reach of an Astellas-partnered therapy.
Astellas joins Trump's Medicaid most-favored-nation pricing deals Astellas agreed to give Medicaid the lowest prices it charges anywhere and to help build US manufacturing in exchange for tariff relief. This limits future US pricing power and could pressure revenue, though tariff relief and goodwill are partial offsets.
The pricing agreement is a direct regulatory hit to Astellas's US drug pricing and a key new overhang.

Zhejiang Huahai Pharmaceutical Co Ltd (600521.CG)

Q3 202624 Jul – 7 Oct 2026

▲4

Huahai's profit surges on API growth, procurement wins, and US recovery

Q1-Q3 profit forecast up 170-190% Huahai expects net profit for the first three quarters of 2026 to jump 170%-190% to 1.03-1.10 billion yuan, driven by API market expansion, domestic procurement share gains, and a turnaround in US finished drug sales. This directly boosts investor confidence and the stock's earnings outlook.
This is the biggest new financial catalyst, showing a sharp profit increase that likely drives the stock price up.
Reciceptimab approved for market Huahai's first-in-class IL-36R antibody Reciceptimab (Huayijing) received marketing approval in China for generalized pustular psoriasis. This strengthens its innovative drug pipeline and opens a new revenue stream, supporting long-term growth and valuation.
A new drug approval is a concrete pipeline win that can lift future earnings and investor sentiment.
Won bids for 4 products in national procurement Huahai won bids for four products in China's 12th national drug procurement, three of which were newly approved in Q2 2026. Winning these bids helps quickly expand domestic hospital sales and market share, though price cuts are typical in such programs.
Procurement wins directly boost domestic sales volume and are a key growth driver cited in the profit forecast.
US tariff refunds and HB0043 trial approval Huahai received over $10 million in US IEEPA tariff refunds, adding a one-time profit boost. Separately, its subsidiary got clinical trial approval for HB0043, a world-first bispecific antibody for hidradenitis suppurativa, advancing its innovative pipeline.
These are new positive developments that improve cash flow and pipeline prospects, though smaller than the profit forecast.

August 202624 Jul – 7 Oct 2026

▲4

Huahai's profit surges on API growth, procurement wins, and US recovery

Q1-Q3 profit forecast up 170-190% Huahai expects net profit for the first three quarters of 2026 to jump 170%-190% to 1.03-1.10 billion yuan, driven by API market expansion, domestic procurement share gains, and a turnaround in US finished drug sales. This directly boosts investor confidence and the stock's earnings outlook.
This is the biggest new financial catalyst, showing a sharp profit increase that likely drives the stock price up.
Reciceptimab approved for market Huahai's first-in-class IL-36R antibody Reciceptimab (Huayijing) received marketing approval in China for generalized pustular psoriasis. This strengthens its innovative drug pipeline and opens a new revenue stream, supporting long-term growth and valuation.
A new drug approval is a concrete pipeline win that can lift future earnings and investor sentiment.
Won bids for 4 products in national procurement Huahai won bids for four products in China's 12th national drug procurement, three of which were newly approved in Q2 2026. Winning these bids helps quickly expand domestic hospital sales and market share, though price cuts are typical in such programs.
Procurement wins directly boost domestic sales volume and are a key growth driver cited in the profit forecast.
US tariff refunds and HB0043 trial approval Huahai received over $10 million in US IEEPA tariff refunds, adding a one-time profit boost. Separately, its subsidiary got clinical trial approval for HB0043, a world-first bispecific antibody for hidradenitis suppurativa, advancing its innovative pipeline.
These are new positive developments that improve cash flow and pipeline prospects, though smaller than the profit forecast.

Latest24 Jul – 7 Oct 2026

▲4

Huahai's profit surges on API growth, procurement wins, and US recovery

Q1-Q3 profit forecast up 170-190% Huahai expects net profit for the first three quarters of 2026 to jump 170%-190% to 1.03-1.10 billion yuan, driven by API market expansion, domestic procurement share gains, and a turnaround in US finished drug sales. This directly boosts investor confidence and the stock's earnings outlook.
This is the biggest new financial catalyst, showing a sharp profit increase that likely drives the stock price up.
Reciceptimab approved for market Huahai's first-in-class IL-36R antibody Reciceptimab (Huayijing) received marketing approval in China for generalized pustular psoriasis. This strengthens its innovative drug pipeline and opens a new revenue stream, supporting long-term growth and valuation.
A new drug approval is a concrete pipeline win that can lift future earnings and investor sentiment.
Won bids for 4 products in national procurement Huahai won bids for four products in China's 12th national drug procurement, three of which were newly approved in Q2 2026. Winning these bids helps quickly expand domestic hospital sales and market share, though price cuts are typical in such programs.
Procurement wins directly boost domestic sales volume and are a key growth driver cited in the profit forecast.
US tariff refunds and HB0043 trial approval Huahai received over $10 million in US IEEPA tariff refunds, adding a one-time profit boost. Separately, its subsidiary got clinical trial approval for HB0043, a world-first bispecific antibody for hidradenitis suppurativa, advancing its innovative pipeline.
These are new positive developments that improve cash flow and pipeline prospects, though smaller than the profit forecast.